Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-054708
Filing Date
2025-04-16
Accepted
2025-04-16 16:05:04
Documents
2
Period of Report
2025-04-14

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2198
2 EX-24 ikt-ex24.htm EX-24 16031
  Complete submission text file 0000950170-25-054708.txt   19659
Mailing Address SUITE 4 LEVEL 46 2 PARK STREET SIDNEY C3 2000
Business Address
McIntyre David (Reporting) CIK: 0001404254 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39676 | Film No.: 25842733

Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)